Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
FBRX

FBRX - Forte Biosciences, Inc. Stock Price, Fair Value and News

0.56USD0.00 (0.00%)Delayed

Market Summary

FBRX
USD0.560.00
Delayed
0.00%

FBRX Stock Price

View Fullscreen

FBRX RSI Chart

FBRX Valuation

Market Cap

20.4M

Price/Earnings (Trailing)

-0.63

Price/Sales (Trailing)

718.72

EV/EBITDA

-0.38

Price/Free Cashflow

-0.67

FBRX Price/Sales (Trailing)

FBRX Profitability

EBT Margin

-132238.89%

Return on Equity

-112.06%

Return on Assets

-100.39%

Free Cashflow Yield

-148.26%

FBRX Fundamentals

FBRX Revenue

Revenue (TTM)

36.0K

FBRX Earnings

Earnings (TTM)

-32.1M

Earnings Growth (Yr)

-9.88%

Earnings Growth (Qtr)

-26.36%

Breaking Down FBRX Revenue

Last 7 days

-3.4%

Last 30 days

-12.5%

Last 90 days

-9.7%

Trailing 12 Months

-45.6%

How does FBRX drawdown profile look like?

FBRX Financial Health

Current Ratio

9.45

Debt/Equity

0.77

Debt/Cashflow

-1.37

FBRX Investor Care

Shares Dilution (1Y)

73.11%

Diluted EPS (TTM)

-0.86

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20200000
201913.5M9.0M4.5M36.0K
2018438.0K666.0K18.7M18.0M
201776.8K104.5K132.3K160.0K
2016106.8K87.5K68.3K49.0K
2015000126.0K

Tracking the Latest Insider Buys and Sells of Forte Biosciences, Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Apr 01, 2024
wagner paul a.
sold (taxes)
-1,735
0.7075
-2,453
see remarks
Apr 01, 2024
wagner paul a.
acquired
-
-
31,250
see remarks
Apr 01, 2024
riley antony a
sold (taxes)
-2,366
0.7075
-3,345
chief financial officer
Apr 01, 2024
riley antony a
acquired
-
-
9,375
chief financial officer
Jan 01, 2024
chen hubert c
sold (taxes)
-2,525
0.8217
-3,073
see remarks
Jan 01, 2024
chen hubert c
acquired
-
-
7,500
see remarks
Jan 01, 2024
wagner paul a.
sold (taxes)
-3,376
0.8217
-4,109
see remarks
Jan 01, 2024
wagner paul a.
acquired
-
-
31,250
see remarks
Jan 01, 2024
riley antony a
sold (taxes)
-3,156
0.8217
-3,841
chief financial officer
Jan 01, 2024
riley antony a
acquired
-
-
9,375
chief financial officer

1–10 of 48

Which funds bought or sold FBRX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 24, 2024
FARALLON CAPITAL MANAGEMENT LLC
unchanged
-
-219,065
1,268,590
0.01%
May 15, 2024
MORGAN STANLEY
unchanged
-
-125
692
-%
May 15, 2024
HSBC HOLDINGS PLC
unchanged
-
-1,174
7,529
-%
May 15, 2024
BANK OF AMERICA CORP /DE/
sold off
-100
-17.00
-
-%
May 15, 2024
FRED ALGER MANAGEMENT, LLC
unchanged
-
-230,791
1,280,290
0.01%
May 15, 2024
LM Advisors LLC
sold off
-100
-2,078
-
-%
May 15, 2024
ADAR1 Capital Management, LLC
new
-
118,709
118,709
0.03%
May 15, 2024
Cable Car Capital LLC
unchanged
-
-255,015
1,414,670
1.95%
May 15, 2024
TYBOURNE CAPITAL MANAGEMENT (HK) LTD
unchanged
-
-454,881
2,523,410
0.43%
May 15, 2024
Tower Research Capital LLC (TRC)
added
101
3,351
8,103
-%

1–10 of 40

Are Funds Buying or Selling FBRX?

Are funds buying FBRX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own FBRX
No. of Funds

Unveiling Forte Biosciences, Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
tybourne capital management (hk) ltd
9.99%
3,630,468
SC 13G
Feb 14, 2024
perceptive advisors llc
9.9%
3,633,635
SC 13G/A
Feb 14, 2024
farallon capital partners, l.p.
1.7%
633,514
SC 13G/A
Feb 14, 2024
alger associates inc
5.1%
1,838,965
SC 13G/A
Jan 11, 2024
bml investment partners, l.p.
4.8%
1,761,702
SC 13D/A
Jan 09, 2024
funicular funds, lp
5.59%
2,031,987
SC 13D/A
Jan 05, 2024
camac fund, lp
4.3%
1,577,176
SC 13D/A
Sep 15, 2023
bml investment partners, l.p.
4.78%
1,735,075
SC 13D/A
Sep 12, 2023
alger associates inc
5.1%
1,838,965
SC 13G
Sep 08, 2023
perceptive advisors llc
9.9%
3,627,775
SC 13G

Recent SEC filings of Forte Biosciences, Inc.

View All Filings
Date Filed Form Type Document
Jun 14, 2024
8-K
Current Report
May 13, 2024
8-K
Current Report
May 13, 2024
10-Q
Quarterly Report
Apr 29, 2024
10-K/A
Annual Report
Apr 12, 2024
S-8
Employee Benefits Plan
Apr 02, 2024
4
Insider Trading
Apr 02, 2024
4
Insider Trading
Mar 25, 2024
4
Insider Trading
Mar 25, 2024
4
Insider Trading
Mar 25, 2024
4
Insider Trading

Peers (Alternatives to Forte Biosciences, Inc.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
53.7B
6.8B
8.51% 7.74%
-8.99
7.84
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
20.3B
2.0B
8.81% -20.73%
-61.09
10.13
75.20% 68.82%
15.9B
2.5B
3.83% -12.90%
77.15
6.41
13.74% 186.89%
13.9B
3.8B
8.85% -0.77%
18.71
3.7
8.58% 129.81%
MID-CAP
5.2B
107.9M
-7.07% 79.45%
-9.53
48.09
54.84% -28.31%
5.1B
524.1M
0.17% -53.14%
-12.21
9.72
394.93% 39.61%
3.5B
251.0M
-2.92% -12.90%
-11.81
13.95
73.58% -86.73%
3.2B
240.7M
3.27% -27.64%
-6.79
12.77
-1.03% -213.92%
2.5B
813.8M
-1.46% -38.91%
-1.4K
3.03
56.43% 98.83%
2.0B
996.6M
11.55% 78.54%
-5.07
2.03
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-9.60% 21.75%
27.32
4.32
60.38% -34.49%
534.3M
881.7K
13.28% 545.16%
-15.83
481.06
-77.61% 33.36%
235.5M
4.2M
-30.45% 48.53%
-1.89
56.62
-66.30% 48.24%
22.1M
2.1M
36.17% 264.31%
-0.95
7.61
-13.45% 69.54%

Forte Biosciences, Inc. News

Latest updates
Defense World13 Jun 202407:42 am
Investing.com India29 May 202407:00 am
Seeking Alpha5 years ago

Forte Biosciences, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q22018Q12017Q42017Q32017Q22017Q12016Q42016Q32016Q22016Q12015Q4
Revenue-70.1%0.000.000.000.006.0012.0018.000.000.000.000.000.000.000.000.000.000.00-
Operating Expenses-81.1%2.0011.001.001.0017.0019.0017.0015.00----------
  S&GA Expenses140.7%1.00-1.650.000.004.003.004.003.00----------
  R&D Expenses-58.6%3.008.0013.0012.0012.0016.0012.0013.0010.008.008.007.007.007.008.007.006.00-
Interest Expenses129.4%1.000.002.001.001.001.001.001.000.000.000.000.001.001.001.001.001.00-
Income Taxes------0.002.00-----------
Earnings Before Taxes100.0%--10.58-18.73---19.411.00----9.95-------
Net Income80.6%-2.05-10.58-0.69-0.63-1.18-19.60-0.38-16.09----------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-17.9%32.0039.0048.0031.0037.0042.0045.0040.0041.0043.0047.0053.0057.0061.0023.0028.0019.008.0071.0085.0095.00
  Current Assets-17.8%32.0038.0047.0031.0036.0042.0045.0039.0040.0043.0047.0052.0056.0060.0022.0028.0015.008.0060.0073.0082.00
    Cash Equivalents-18.0%30.0037.0046.0020.0036.0041.0044.0039.0040.0042.0046.0051.0055.0059.0020.0028.004.007.008.008.0031.00
  Net PPE-2.8%0.000.000.000.00-------0.000.000.000.000.001.000.004.004.004.00
Liabilities-----------------17.0017.0051.0049.0050.00
  Current Liabilities-9.1%3.004.007.006.004.003.002.002.001.002.004.003.002.002.002.003.0013.002.0042.0017.0016.00
  Long Term Debt--------------------22.0024.00
    LT Debt, Non Current--------------------22.0024.00
Shareholder's Equity-18.8%29.0035.0040.0025.0033.0039.0043.0038.0040.0042.0044.0050.0055.0059.0020.0025.002.0011.0020.0036.0045.00
  Retained Earnings-6.2%-125-118-112-102-93.80-87.04-82.20-78.80-75.70-73.17-69.82-62.07-56.30-51.46-46.88-41.78-289-4.97-268-250-232
  Additional Paid-In Capital0.5%15515415312812712612511711611511311211111067.0067.002920.00289286278
Accumulated Depreciation100.0%0.000.00---------------2.00---
Shares Outstanding0.2%36.0036.0036.0021.0021.0021.0021.0015.0015.0015.0014.0014.00---------
Float----20.00---18.00---396---72.00---223-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations25.7%-6,667-8,969-9,037-5,496-5,204-2,893-1,940-1,377-1,975-3,582-5,127-3,938-4,030-3,803-7,739-4,016-2,865-653-55316,117-17,682
  Share Based Compensation3.2%8057807728558778609061,1941,0551,2381,4731,00849555537524.002.0031.002.00-1,9972,000
Cashflow From Investing62.5%-6.00-16.0010,028------------1.00-9,13912,722-89.00-5,764-4066,097
Cashflow From Financing89.3%-8.00-75.0024,777-24.006.00-55.007,440-110-34.00-39.00-3.00-29.0027.0042,39316624,06345.00--3,0861,770
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

FBRX Income Statement

2024-03-31
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Operating expenses:  
Research and development (including $29 and $0 of related party transactions for the 3 months ending March 31, 2024 and 2023, respectively)$ 4,353$ 4,787
General and administrative3,4512,068
Total operating expenses7,8046,855
Loss from operations(7,804)(6,855)
Other income, net384102
Net loss$ (7,420)$ (6,753)
Net loss per share - basic$ (0.16)$ (0.32)
Net loss per share - diluted$ (0.16)$ (0.32)
Weighted average shares and pre-funded warrants outstanding, basic46,082,86121,006,680
Weighted average shares and pre-funded warrants outstanding, diluted46,082,86121,006,680
Comprehensive Loss:  
Net loss$ (7,420)$ (6,753)
Unrealized loss on available-for-sale securities(6) 
Comprehensive loss$ (7,426)$ (6,753)

FBRX Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 30,444$ 37,125
Prepaid expenses and other current assets1,0581,202
Total current assets31,50238,327
Property and equipment, net106109
Other assets409544
Total assets32,01738,980
Current liabilities:  
Accounts payable1,6851,424
Accrued liabilities1,6472,242
Total current liabilities3,3323,666
Commitments and contingencies (Note 6)
Stockholders’ equity  
Common stock, $0.001 par value: 200,000,000 shares authorized as of March 31, 2024 (unaudited) and December 31, 2023; 36,394,882 and 36,335,105 shares issued and outstanding as of March 31, 2024 (unaudited) and December 31, 2023, respectively3636
Additional paid-in capital154,591153,794
Accumulated other comprehensive income (loss)(2)4
Accumulated deficit(125,940)(118,520)
Total stockholders’ equity28,68535,314
Total liabilities and stockholders' equity$ 32,017$ 38,980
FBRX
Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.
 CEO
 WEBSITEfortebiorx.com
 INDUSTRYBiotechnology
 EMPLOYEES7

Forte Biosciences, Inc. Frequently Asked Questions


What is the ticker symbol for Forte Biosciences, Inc.? What does FBRX stand for in stocks?

FBRX is the stock ticker symbol of Forte Biosciences, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Forte Biosciences, Inc. (FBRX)?

As of Fri Jun 14 2024, market cap of Forte Biosciences, Inc. is 20.41 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of FBRX stock?

You can check FBRX's fair value in chart for subscribers.

What is the fair value of FBRX stock?

You can check FBRX's fair value in chart for subscribers. The fair value of Forte Biosciences, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Forte Biosciences, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for FBRX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Forte Biosciences, Inc. a good stock to buy?

The fair value guage provides a quick view whether FBRX is over valued or under valued. Whether Forte Biosciences, Inc. is cheap or expensive depends on the assumptions which impact Forte Biosciences, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for FBRX.

What is Forte Biosciences, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jun 14 2024, FBRX's PE ratio (Price to Earnings) is -0.63 and Price to Sales (PS) ratio is 718.72. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. FBRX PE ratio will change depending on the future growth rate expectations of investors.